Establishment Labs (NASDAQ:ESTA) Shares Gap Down - Should You Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $31.32, but opened at $30.53. Establishment Labs shares last traded at $31.83, with a volume of 62,015 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Stephens reiterated an "overweight" rating and issued a $52.00 price target on shares of Establishment Labs in a research note on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a report on Monday, April 14th. They issued a "hold" rating for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.40.

Establishment Labs Price Performance

The firm has a fifty day moving average of $36.56 and a 200 day moving average of $39.69. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. The company has a market capitalization of $907.21 million, a P/E ratio of -12.19 and a beta of 0.77.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The company had revenue of $44.51 million during the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. On average, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Elevation Point Wealth Partners LLC purchased a new stake in Establishment Labs during the first quarter valued at $207,000. Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Establishment Labs during the 1st quarter valued at about $234,000. Toronto Dominion Bank purchased a new stake in shares of Establishment Labs during the 4th quarter valued at about $24,879,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Establishment Labs by 15.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,658 shares of the company's stock worth $2,196,000 after purchasing an additional 6,307 shares during the period. Finally, Union Square Park Capital Management LLC boosted its holdings in shares of Establishment Labs by 47.0% in the fourth quarter. Union Square Park Capital Management LLC now owns 160,000 shares of the company's stock worth $7,371,000 after buying an additional 51,192 shares during the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.